Registration 333-263328
Underwriters: ThinkEquity LLC
Company research
CIK 1880995Updated Nov 9, 2026
27 filings on record · S-1/A, FWP, 8-A12B, S-1, DRS.
We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, was found to be well tolerated with no serious adverse events observed. It was noted to induce antibodies in human serum that were effective, in laboratory studies, in killing all PNAG-expressing pathogens tested. We believe our vaccine’s broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis, and sexually transmitted diseases. Similarly, our fully human mo…
Underwriters: ThinkEquity LLC
EX-FILING FEES 9 ex107.htm CALCULATION OF FILING FEE TABLE ALOPEXX, INC. S-1/A Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Alopexx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Security Fee Amount Proposed Maximum …
Read attachment ↗